 | • レポートコード：MRC23Q35856 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のCAR T細胞療法市場について調査・分析し、世界のCAR T細胞療法市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（CD19-対象、BCMA-対象）、用途別セグメント分析（リンパ腫、多発性骨髄腫）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、Autolus Therapeutics(Pipeline)、Sorrento Therapeutics(Pipeline)、Mustang Bio(Pipeline)、Bluebird Bio(Pipeline)、Cellectis(Pipeline)、Allogene Therapeutics(Pipeline)、Celyad(Pipeline)などが含まれています。世界のCAR T細胞療法市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、CAR T細胞療法市場規模を推定する際に考慮しました。本レポートは、CAR T細胞療法の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、CAR T細胞療法に関するビジネス上の意思決定に役立てることを目的としています。 ・CAR T細胞療法市場の概要 - CAR T細胞療法のタイプ別セグメント - 世界のCAR T細胞療法市場規模：タイプ別分析（CD19-対象、BCMA-対象） - CAR T細胞療法の用途別セグメント - 世界のCAR T細胞療法市場規模：用途別分析（リンパ腫、多発性骨髄腫） - 世界のCAR T細胞療法市場規模予測（2018年-2029年） ・CAR T細胞療法市場の成長トレンド - CAR T細胞療法の地域別市場規模（2018年-2029年） - CAR T細胞療法市場ダイナミクス - CAR T細胞療法の業界動向 - CAR T細胞療法市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：CD19-対象、BCMA-対象 - 世界のCAR T細胞療法のタイプ別市場規模（2018年-2023年） - 世界のCAR T細胞療法のタイプ別市場規模（2024年-2029年） ・用途別セグメント：リンパ腫、多発性骨髄腫 - 世界のCAR T細胞療法の用途別市場規模（2018年-2023年） - 世界のCAR T細胞療法の用途別市場規模（2024年-2029年） ・CAR T細胞療法の地域別市場規模 - 北米のCAR T細胞療法市場規模（2018年-2029年） - アメリカのCAR T細胞療法市場規模（2018年-2029年） - ヨーロッパのCAR T細胞療法市場規模（2018年-2029年） - アジア太平洋のCAR T細胞療法市場規模（2018年-2029年） - 中国のCAR T細胞療法市場規模（2018年-2029年） - 日本のCAR T細胞療法市場規模（2018年-2029年） - 韓国のCAR T細胞療法市場規模（2018年-2029年） - インドのCAR T細胞療法市場規模（2018年-2029年） - オーストラリアのCAR T細胞療法市場規模（2018年-2029年） - 中南米のCAR T細胞療法市場規模（2018年-2029年） - 中東・アフリカのCAR T細胞療法市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、Autolus Therapeutics(Pipeline)、Sorrento Therapeutics(Pipeline)、Mustang Bio(Pipeline)、Bluebird Bio(Pipeline)、Cellectis(Pipeline)、Allogene Therapeutics(Pipeline)、Celyad(Pipeline) ・アナリストの観点/結論 ・調査方法とデータソース |
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Highlights
The global CAR T-Cell Therapy market was valued at US$ 2805.8 million in 2022 and is anticipated to reach US$ 13510 million by 2029, witnessing a CAGR of 29.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy.
The CAR T-Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CAR T-Cell Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR T-Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
Autolus Therapeutics(Pipeline)
Sorrento Therapeutics(Pipeline)
Mustang Bio(Pipeline)
Bluebird Bio(Pipeline)
Cellectis(Pipeline)
Allogene Therapeutics(Pipeline)
Celyad(Pipeline)
Segment by Type
CD19 – Targeted
BCMA – Targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CD19 – Targeted
1.2.3 BCMA – Targeted
1.3 Market by Application
1.3.1 Global CAR T-Cell Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy Market Perspective (2018-2029)
2.2 CAR T-Cell Therapy Growth Trends by Region
2.2.1 Global CAR T-Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CAR T-Cell Therapy Historic Market Size by Region (2018-2023)
2.2.3 CAR T-Cell Therapy Forecasted Market Size by Region (2024-2029)
2.3 CAR T-Cell Therapy Market Dynamics
2.3.1 CAR T-Cell Therapy Industry Trends
2.3.2 CAR T-Cell Therapy Market Drivers
2.3.3 CAR T-Cell Therapy Market Challenges
2.3.4 CAR T-Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2018-2023)
3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2018-2023)
3.2 Global CAR T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell Therapy Revenue
3.4 Global CAR T-Cell Therapy Market Concentration Ratio
3.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Revenue in 2022
3.5 CAR T-Cell Therapy Key Players Head office and Area Served
3.6 Key Players CAR T-Cell Therapy Product Solution and Service
3.7 Date of Enter into CAR T-Cell Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell Therapy Breakdown Data by Type
4.1 Global CAR T-Cell Therapy Historic Market Size by Type (2018-2023)
4.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2024-2029)
5 CAR T-Cell Therapy Breakdown Data by Application
5.1 Global CAR T-Cell Therapy Historic Market Size by Application (2018-2023)
5.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CAR T-Cell Therapy Market Size (2018-2029)
6.2 North America CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CAR T-Cell Therapy Market Size by Country (2018-2023)
6.4 North America CAR T-Cell Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy Market Size (2018-2029)
7.2 Europe CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CAR T-Cell Therapy Market Size by Country (2018-2023)
7.4 Europe CAR T-Cell Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy Market Size (2018-2029)
8.2 Asia-Pacific CAR T-Cell Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR T-Cell Therapy Market Size (2018-2029)
9.2 Latin America CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CAR T-Cell Therapy Market Size by Country (2018-2023)
9.4 Latin America CAR T-Cell Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy Market Size (2018-2029)
10.2 Middle East & Africa CAR T-Cell Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR T-Cell Therapy Introduction
11.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR T-Cell Therapy Introduction
11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 J & J
11.4.1 J & J Company Detail
11.4.2 J & J Business Overview
11.4.3 J & J CAR T-Cell Therapy Introduction
11.4.4 J & J Revenue in CAR T-Cell Therapy Business (2018-2023)
11.4.5 J & J Recent Development
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Detail
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR T-Cell Therapy Introduction
11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2018-2023)
11.5.5 JW Therapeutics Recent Development
11.6 FOSUNKite
11.6.1 FOSUNKite Company Detail
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR T-Cell Therapy Introduction
11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2018-2023)
11.6.5 FOSUNKite Recent Development
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Detail
11.7.2 CARsgen Therapeutics (Pipeline) Business Overview
11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Introduction
11.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.7.5 CARsgen Therapeutics (Pipeline) Recent Development
11.8 Autolus Therapeutics(Pipeline)
11.8.1 Autolus Therapeutics(Pipeline) Company Detail
11.8.2 Autolus Therapeutics(Pipeline) Business Overview
11.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.8.4 Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.8.5 Autolus Therapeutics(Pipeline) Recent Development
11.9 Sorrento Therapeutics(Pipeline)
11.9.1 Sorrento Therapeutics(Pipeline) Company Detail
11.9.2 Sorrento Therapeutics(Pipeline) Business Overview
11.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.9.4 Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.9.5 Sorrento Therapeutics(Pipeline) Recent Development
11.10 Mustang Bio(Pipeline)
11.10.1 Mustang Bio(Pipeline) Company Detail
11.10.2 Mustang Bio(Pipeline) Business Overview
11.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Introduction
11.10.4 Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.10.5 Mustang Bio(Pipeline) Recent Development
11.11 Bluebird Bio(Pipeline)
11.11.1 Bluebird Bio(Pipeline) Company Detail
11.11.2 Bluebird Bio(Pipeline) Business Overview
11.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Introduction
11.11.4 Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.11.5 Bluebird Bio(Pipeline) Recent Development
11.12 Cellectis(Pipeline)
11.12.1 Cellectis(Pipeline) Company Detail
11.12.2 Cellectis(Pipeline) Business Overview
11.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Introduction
11.12.4 Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.12.5 Cellectis(Pipeline) Recent Development
11.13 Allogene Therapeutics(Pipeline)
11.13.1 Allogene Therapeutics(Pipeline) Company Detail
11.13.2 Allogene Therapeutics(Pipeline) Business Overview
11.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Introduction
11.13.4 Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.13.5 Allogene Therapeutics(Pipeline) Recent Development
11.14 Celyad(Pipeline)
11.14.1 Celyad(Pipeline) Company Detail
11.14.2 Celyad(Pipeline) Business Overview
11.14.3 Celyad(Pipeline) CAR T-Cell Therapy Introduction
11.14.4 Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2018-2023)
11.14.5 Celyad(Pipeline) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
